Clinical nephrologyClinical nephrologyКлиническая нефрология2075-35942414-9322Bionika Media245929ArticlesСтатьиTreatment of anemia with methoxypolyethyleneglycol - epoetin beta in patients on haemodyalisisЛечение анемии метоксиполиэтиленгликолем-эпоэтином бета у больных, получающих гемодиализShutovE VШутовЕ В

ГКБ им. С.П. Боткина, Москва

LashutinS VЛашутинС В

ГКБ им. С.П. Боткина, Москва

KolomiytsevaI GКоломийцеваИ Г

ГКБ им. С.П. Боткина, Москва

ShuvalovE VШуваловЕ В

ГКБ им. С.П. Боткина, Москва

ГКБ им. С.П. Боткина, Москва150420112NO2 (2011)№2 (2011)141917022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2075-3594/article/view/245929

Aim. Determination of efficacy and safety of methoxypolyethyleneglycol-epoetin beta (MEB) in patients with terminal renal failure on hemodyalysis, who previously received recombinant human erythropoietin (rhEPO) preparations. Methods. 30 patients (14 male, 16 female, mean age 58,5±14,6 years) with terminal renal failure on hemodyalysis were included into prospective study. Baseline hemoglobin (Hb) level was 100 - 130 g/l. All patients were switched from rhEPO to MEB. Duration of study was 12 months. Results. Mean Hb level at the end of the study was 115,5±13,2 g/l; mean haematocrit level - (Hct) - 33,4±3,2%; no significant difference from baseline levels was detected. Target Hb level was maintained with MEB in 12 months in 85%. Blood pressure levels were stable. MEB was well tolerated. Conclusion. MEB is effective in maintenance of Hb level in patient on hemodialysis, previously treated with rhEPO

Цель. Оценка эффективности, безопасности и переносимости метоксиполиэтиленгликоля-бета (МЭБ) при внутривенном введении 1 раз в месяц для поддержания стабильного уровня гемоглобина у пациентов с нефрогенной анемией, находящихся на программном гемодиализе, получавших ранее терапию препаратами рекомбинантного человеческого эритропоэтина (рчЭПО) I поколения (эпокрин, рекормон). Материал и методы. В проспективное исследование были включены 30 стабильных больных (14 мужчин и 16 женщин, средний возраст 58,5±14,6 лет) с терминальной почечной недостаточностью (ТПН), получавших лечение программным ГД. Уровень гемоглобина исходно составлял 100 - 130 г/л. Всех больных переводили с препаратов рчЭПО на МЭБ, дозу которого рассчитывали исходя из предшествующей дозы рчЭПО. Продолжительность исследования составила 12 месяцев. Результаты. Средний уровень Hb к концу исследования составил 115,5±13,2 г/л; средняя величина гематокрита (Hct) - 33,4±3,2%; достоверной динамики этих показателей при переводе с рчЭПО на МЭБ отмечено не было. Целевой уровень Hb в течение 12 месяцев удалось поддерживать с помощью МЭБ у 85%. Средняя доза МЭБ в начале исследования составила 110±31 мкг/мес, к 4 месяцу лечения - 143±51 мкг/мес, к концу исследования - составила 113±61 мкг/мес Величины АД были стабильными, переносимость МЭБ была хорошей. Заключение. Применение МЭБ позволяет эффективно управлять уровнем Hb у больных на программном гемодиализе, ранее получавших рчЭПО

methoxypolyethyleneglycol-epoetin betacontinuous erythropoietin receptor activatorterminal renal failureanemiaметоксиполиэтиленгликоль-бетатерминальная почечная недостаточностьанемиялечениеБиблиографияЗемченков А.Ю., Герасимчук Р.П., Костылева Т.Г. и др. Оценка эффективности и безопасности нового отечественного препарата - эритропоэтина альфа. // Нефрология и диализ, 2010. Т.12, №4, С.289-296.Adamson JW. Iron deficiency and other hypoproliferative anemias. // In: Harrison's Principles of Internal Medicine / Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, 16th ed. New York, NY: McGraw-Hill. 2005. P. 586-592.Cain SM. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977; 42:228-234.Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study // Nephrol Dial Transplant. 2008.Vol. 23(11). P. 3654-3661.Carrera F, Lok CE, de Francisco A. et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxypolyethyleneglycol - epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. // Nephrol Dial Transplant. 2010. Vol. 25(12). P. 4009-4017.Drueke TB, Locatelli F, Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. // N Engl J Med. 2006. Vol. 355. P. 2071-2084.Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. // Clin J Am Soc Nephrol. 2006; Vol.1, P. 1205-1210.Eckardt KU, Kim J, Kronenberg F. et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. // Am Soc Nephrol. 2010. Vol. 21(10). P.1765-1775.Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? // Semin Dial. 2006. Vol. 19. P.1-4.Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. // Kidney Int 2005. Vol.68. P.1337-1343.Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. // Pharmacology. 2008. Vol. 81. P.63-69.Klinger M., Arias M., Vargemezis V. et al. Efficacy of intravenous methoxypolyethyleneglycol-epoietin beta administered every 2 weeks compared with epoietin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. // Am. J. Kidney Dis. 2007. Vol. 50. P. 989-1000.Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. // Nephrol Dial Transplant. 2010. Vol. 25(12) P.4002-4009.Levin NW, Fishbane S, Valdés Cañedo F. et al. On behalf of the MAXIMA study investigators. Intravenous methoxypolyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). // Lancet. 2007. Vol. 370. P. 1415-1421.Li S, C Besarab A, Bolton WK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. // N Engl J Med. 1998. Vol.339. P. 584 -590.Locatelli F., Mann J., Aldigier J. et al. C.E.R.A. safety profile a pooled analysis in patients with chronic kidney disease. // Clinical Nephrology. 2010. Vol. 73. P. 94-103.Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. // Lancet. 2006. Vol. 368. P. 947-953.Macdougall IC, Robson R., Opatrna S. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. //.Clin J Am Soc Nephrol. 2006. Vol. 1. P. 1211-1215.Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesisstimulating agent for the treatment of anemia. // Curr Hematol Rep. 2005.Vol. 4.P. 436-440.Manley H., Debra R., Drayer R., et al. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. // BMC Nephrol. 2003. Vol. 4. P. 4-10.Manley H., Cannela C., Bailie C., St. Peter W. Medication-related problem in ambulatory hemodialysis patients a pooled analysis. // Am J Kidney Dis 2005. Vol.46(4) P. 669-680.McClellan W., Jurkovitz C., Abramson J. The epidemiology and control of anemia among pre-ESRD patients with chronic kidney disease. // Eur. J. Clin Investig. 2005. Vol. 35, Suppl. 3. P. 58-65Pisoni RL, Bragg-Gresham JL, Fuller DS et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. // Am J Kidney Dis. 2011. Vol. 57(2), P. 266-275.Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. // N Engl J Med. 2006. Vol. 355. P. 2085-2098.Spinowitz B, Coyne DW, Lok CE. RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. // Am J Nephrol. 2008. Vol. 28. P. 280-289.Sulowicz W., Locatelli F., Ryckenlynck J-P. et al. On behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic Kidney disease on dialysis converted directly from epoetin one to three times weekly. // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. P. 637-646.Weinhandl ED, Peng Y, Gilbertson DT et al. Hemoglobin variability and mortality: confounding by disease severity. // Am J Kidney Dis. 2011. Vol. 57(2). P. 255-265.Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. // J Am Soc Nephrol. 2007. Vol. 18. P. 3164-3170.